title: Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy.
abstract: The aim of this study was to compare overall survival (OS), progression-free survival (PFS), and relapse patterns between different modalities of treatment for uterine papillary serous carcinoma (UPSC). A retrospective review of 124 patients with pathologically confirmed UPSC was performed, of whom, 97 patients were eligible for study. Postoperative treatment groups included adjuvant radiotherapy consisting of whole abdomen and a pelvic boost (abdominopelvic radiotherapy [APRT]) (55 patients), paclitaxel and carboplatin chemotherapy (CT) for six cycles followed by APRT (18 patients), CT only (5 patients), and 19 patients were observed without postoperative adjuvant therapy. Three-year OS was 81% and 63% for the CT followed by APRT and APRT alone, respectively (P= 0.11). After controlling for stage, the group treated with APRT alone had significantly decreased OS and PFS compared to the CT/APRT group (HR 3.6; 1.3-9.8; P= 0.01) and (HR 2.9; 95% CI 1.1-7.3; P= 0.03), respectively. Within the limitations of a retrospective study, the results of this study indicate that multimodality postoperative treatment with paclitaxel and a platinum-based CT followed by APRT may increase the survival of patients with UPSC. However, further prospective studies using these combined modalities are needed to confirm these findings.
authors.affiliation: Department of Gynecology Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.
authors.forename: H
authors.initials: H
authors.lastname: Steed
authors.forename: L
authors.initials: L
authors.lastname: Manchul
authors.forename: B
authors.initials: B
authors.lastname: Rosen
authors.forename: A
authors.initials: A
authors.lastname: Fyles
authors.forename: G
authors.initials: G
authors.lastname: Lockwood
authors.forename: S
authors.initials: S
authors.lastname: Laframboise
authors.forename: J
authors.initials: J
authors.lastname: Murphy
authors.forename: M
authors.initials: M
authors.lastname: Milosevic
authors.forename: W
authors.initials: W
authors.lastname: Chapman
authors.forename: A M
authors.initials: AM
authors.lastname: Oza
mesh_terms: D000231:Adenocarcinoma, Papillary / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D013509:Gynecologic Surgical Procedures; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D017239:Paclitaxel / Q000008:administration & dosage; D011878:Radiotherapy; D012189:Retrospective Studies; D016019:Survival Analysis; D014594:Uterine Neoplasms / Q000628:therapy*
chemical_list: D016190:Carboplatin; D017239:Paclitaxel